This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Kudos to Keryx, but Can Zerenex Zing?

Stocks in this article: KERX SNY AMGN DVA AMAG

NEW YORK ( TheStreet) --Congratulations, Keryx Pharmaceuticals (KERX) . The long-term data on its phosphate binder Zerenex released Monday morning look very strong, sending Keryx shares higher by 43% in early trading.

Zerenex met the study's primary goal of reducing serum phosphate levels in kidney dialysis patients, which wasn't a surprise to anyone. More importantly, however, Zerenex demonstrated significant benefits related to increased iron stores and reducing the use of IV iron and erythropoietin-stimulating agents (ESAs) like Amgen's (AMGN) Epogen.

It's these latter iron benefits that help Zerenex stand apart from other phosphate binders such as Sanofi's (SNY) Renagel/Renvela, the market leader with nine-month 2012 sales of $640 million worldwide. (Sanofi reports year-end sales next month.) Based on today's study results, Zerenex should have an easy time being approved in early 2014. That's the same time period at which less expensive, generic versions of Renvela -- in addition to generic versions of IV irons -- will also become available to kidney dialysis clinics.

Keryx has long maintained that Zerenex can grab significant market share in kidney dialysis clinics even competing against low-priced, generic phosphate binders. During a conference call Monday, Keryx CEO Ron Bentsur said U.S. dialysis clinics could save $750 million annually from reduced use of IV iron and ESAs if they switched to Zerenex.

"Generic Renvela doesn't have the capacity to compete with the magnitude of these cost savings," said Bentsur.

AMAG Pharmaceuticals (AMAG) CEO Brian Pereira once made similarly bold pronouncements about how his clinically superior IV iron therapy Feraheme was going to be grab significant kidney dialysis market share from its competitors. That never happened, which forced AMAG to all but abandon the kidney dialysis market.

Perhaps Keryx will buck the trend and convince dialysis providers like DaVita (DVA) and Fresenius that they can save money by using a more expensive phosphate binder when cheaper alternatives are available. Monday's Zerenex data seem to bolster Keryx's argument. I'm not sure skeptics will be entirely convinced until Keryx lands a Big Pharma partner willing to shell out big bucks to license Zerenex, or the drug launches strong.

That's a fight for another day. Monday, Keryx deserves credit for delivering a clear win with the Zerenex clinical data, and in the process, helping erase the sting and stigma left from last year's perifosine colon cancer blowup.

Keryx shares are up 43% to $4.89 in early trading.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs